Header Logo

Connection

Robin Jones to Sarcoma

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Sarcoma.
Robin Jones
Connection Strength
21.658
Sarcoma
  1. Management of Vascular Sarcoma. Surg Oncol Clin N Am. 2022 07; 31(3):485-510.
    View in: PubMed
    Score: 0.654
  2. The evolving management of epithelioid sarcoma. Eur J Cancer Care (Engl). 2021 Nov; 30(6):e13489.
    View in: PubMed
    Score: 0.612
  3. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
    View in: PubMed
    Score: 0.604
  4. Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. Oncology. 2021; 99 Suppl 1:8-16.
    View in: PubMed
    Score: 0.601
  5. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866.
    View in: PubMed
    Score: 0.596
  6. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
    View in: PubMed
    Score: 0.584
  7. Sirolimus for patients with progressive epithelioid hemangioendothelioma. Cancer. 2021 02 15; 127(4):504-506.
    View in: PubMed
    Score: 0.582
  8. Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. Int J Surg Pathol. 2021 Feb; 29(1):4-20.
    View in: PubMed
    Score: 0.577
  9. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 08; 5(4).
    View in: PubMed
    Score: 0.573
  10. Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020 07; 6:1046-1051.
    View in: PubMed
    Score: 0.569
  11. Ewing-like sarcomas: New molecular diagnoses in need of optimized treatment approaches. Indian J Med Res. 2019 12; 150(6):521-523.
    View in: PubMed
    Score: 0.547
  12. Negative phase III trials announce the need for biomarkers in sarcoma. Eur J Cancer. 2019 12; 123:81-82.
    View in: PubMed
    Score: 0.543
  13. Sarcomas and old age: few options for such a large patient population. Future Oncol. 2019 Sep; 15(26s):11-15.
    View in: PubMed
    Score: 0.538
  14. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 07 15; 125(14):2445-2454.
    View in: PubMed
    Score: 0.525
  15. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan; 39(1):347-351.
    View in: PubMed
    Score: 0.513
  16. Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
    View in: PubMed
    Score: 0.504
  17. Quality of life and patients' expectations in soft tissue sarcoma. Future Oncol. 2018 May; 14(10s):51-62.
    View in: PubMed
    Score: 0.490
  18. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
    View in: PubMed
    Score: 0.489
  19. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
    View in: PubMed
    Score: 0.482
  20. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018 02; 41(2):147-151.
    View in: PubMed
    Score: 0.482
  21. Systemic therapy in retroperitoneal sarcoma management. J Surg Oncol. 2018 Jan; 117(1):87-92.
    View in: PubMed
    Score: 0.476
  22. Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes? Nat Rev Clin Oncol. 2017 10; 14(10):589-590.
    View in: PubMed
    Score: 0.466
  23. Olaratumab for the treatment of soft-tissue sarcoma. Future Oncol. 2017 Oct; 13(24):2151-2157.
    View in: PubMed
    Score: 0.465
  24. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017 07; 29(4):260-267.
    View in: PubMed
    Score: 0.462
  25. Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? Lancet Oncol. 2017 06; 18(6):706-707.
    View in: PubMed
    Score: 0.460
  26. Phase III Soft Tissue Sarcoma Trials: Success or Failure? Curr Treat Options Oncol. 2017 03; 18(3):19.
    View in: PubMed
    Score: 0.452
  27. Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncol. 2017 Jan; 13(1s):13-21.
    View in: PubMed
    Score: 0.447
  28. Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394.
    View in: PubMed
    Score: 0.445
  29. Drug repositioning in sarcomas and other rare tumors. EBioMedicine. 2016 Apr; 6:4-5.
    View in: PubMed
    Score: 0.423
  30. Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. Int J Surg Pathol. 2016 Feb; 24(1):5-15.
    View in: PubMed
    Score: 0.409
  31. Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37.
    View in: PubMed
    Score: 0.389
  32. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83.
    View in: PubMed
    Score: 0.382
  33. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013 Oct; 9(10):1409-11.
    View in: PubMed
    Score: 0.351
  34. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7.
    View in: PubMed
    Score: 0.329
  35. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9.
    View in: PubMed
    Score: 0.292
  36. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2022 Nov; 29(12):7335-7348.
    View in: PubMed
    Score: 0.163
  37. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. Eur J Cancer. 2022 08; 171:183-192.
    View in: PubMed
    Score: 0.163
  38. Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. Expert Rev Anticancer Ther. 2022 Jan; 22(1):83-95.
    View in: PubMed
    Score: 0.157
  39. Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis. Anticancer Res. 2021 Oct; 41(10):5089-5096.
    View in: PubMed
    Score: 0.155
  40. Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncol. 2021 Sep; 17(27):3627-3636.
    View in: PubMed
    Score: 0.154
  41. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. Cells. 2021 06 17; 10(6).
    View in: PubMed
    Score: 0.152
  42. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942.
    View in: PubMed
    Score: 0.151
  43. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021 04; 10(8):2645-2659.
    View in: PubMed
    Score: 0.149
  44. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology. 2020 11 19; 9(1):1847846.
    View in: PubMed
    Score: 0.146
  45. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1778-1782.
    View in: PubMed
    Score: 0.146
  46. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
    View in: PubMed
    Score: 0.145
  47. SMARCA4-Deficient Thoracic Sarcoma. Int J Surg Pathol. 2021 Sep; 29(6):640-641.
    View in: PubMed
    Score: 0.142
  48. Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. BMJ Open. 2020 06 01; 10(6):e035171.
    View in: PubMed
    Score: 0.142
  49. Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. J Adolesc Young Adult Oncol. 2020 12; 9(6):628-638.
    View in: PubMed
    Score: 0.141
  50. Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Rev Anticancer Ther. 2020 04; 20(sup1):15-28.
    View in: PubMed
    Score: 0.141
  51. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 04 07; 323(13):1266-1276.
    View in: PubMed
    Score: 0.140
  52. Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. Anticancer Res. 2019 Nov; 39(11):6223-6230.
    View in: PubMed
    Score: 0.136
  53. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
    View in: PubMed
    Score: 0.135
  54. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
    View in: PubMed
    Score: 0.133
  55. Aldoxorubicin in soft tissue sarcomas. Future Oncol. 2019 May; 15(13):1429-1435.
    View in: PubMed
    Score: 0.130
  56. Age-related sarcoma patient experience: results from a national survey in England. BMC Cancer. 2018 Oct 17; 18(1):991.
    View in: PubMed
    Score: 0.126
  57. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.125
  58. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 09 01; 4(9):e180219.
    View in: PubMed
    Score: 0.125
  59. Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. Anticancer Res. 2018 Jul; 38(7):4041-4046.
    View in: PubMed
    Score: 0.124
  60. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan; 210(1):175-182.
    View in: PubMed
    Score: 0.118
  61. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
    View in: PubMed
    Score: 0.115
  62. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810.
    View in: PubMed
    Score: 0.112
  63. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905.
    View in: PubMed
    Score: 0.110
  64. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
    View in: PubMed
    Score: 0.107
  65. Epithelioid Sarcoma: Diagnostic Features and Genetics. Adv Anat Pathol. 2016 Jan; 23(1):41-9.
    View in: PubMed
    Score: 0.104
  66. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11.
    View in: PubMed
    Score: 0.089
  67. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010 May-Jun; 16(3):183-94.
    View in: PubMed
    Score: 0.070
  68. EWSR1-SMAD3-Positive Fibroblastic Tumor. Int J Surg Pathol. 2021 Apr; 29(2):179-181.
    View in: PubMed
    Score: 0.036
  69. Superficial CD34-Positive Fibroblastic Tumor. Int J Surg Pathol. 2020 Dec; 28(8):879-881.
    View in: PubMed
    Score: 0.036
  70. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. Br J Cancer. 2016 08 09; 115(4):473-9.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.